Abstract
The administration of intravenous levosimendan (0.1–0.4 μg/kg per minute) was associated with a statistically significant reduction in plasma levels of endothelin-1 (ET-1) in 79 patients with advanced (New York Heart Association functional class III or IV) heart failure. These data are compatible with the premise that reduction in ET-1 levels contributes to the hemodynamic effects of levosimendan in heart failure, although more extensive investigations are needed to confirm this hypothesis. The present study provided no evidence that levosimendan, in the doses used, had a significant effect on plasma levels of norepine- phrine.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
